DelveInsight Blogs Sitemap

All Posts in this category
S.No. Product Name Actions
1 Pfizer’s RSV Vaccine; Forte Biosciences’ Atopic Dermatitis Asset; Bone Therapeutics’ Osteoarthritis Programme; JandJ's HIV Vaccine Trial; Versanis Bio $70 M Series A Financing; AC Immune's Alzheimer's Antibody Drug Visit Post
2 Ascendis's SKYTROFA; MicroTransponder’s VNS System (Vivistim); BioMarin's Voxzogo; Zimmer-Canary's Smart Knee Implant; COVID-19 impact on Solid Organ Transplants Visit Post
3 Analyzing the Implication of Musculoskeletal Disorders and the Key Companies in the Therapeutics Market Visit Post
4 Diagnosis Delays, Ineffective Treatment Options Plaque the Bone Cancer Market Growth Visit Post
5 Pfizer hit by DMD delay & halts BCMA trials; Sarepta's drug shows promise in Phase II; Human organ chips enable COVID-19 drug repurposing; AbCellera takes new antibody into clinic Visit Post
6 How Is Osteoporosis Impacting The Quality Of Life? Visit Post
7 MedTech Industry Roars Back as FDA Approvals Soar Visit Post
8 A New Addition to Existing Chimeric Antigen Receptor Therapies –Potential for a Game Changer in Blood Cancers Visit Post
9 Bright Peak, Ajinomoto to Create Novel Immunocytokines; FDA’s Rejection to Lilly/Pfizer's Tanezumab for Osteoarthritis Pain; Ikena Oncology Unveils IPO Pricing Visit Post
10 Emerging Therapies in the Chronic Pain Pipeline Transforming the Chronic Pain Market Landscape Visit Post
11 How Robots Are Introducing A New Dimension To Healthcare Service Delivery Visit Post
12 A Need for Curative Treatment Expected to Attract the Pharma Players in the Hallux Valgus Market Landscape Visit Post
13 Parkinson's Disease: How close are we to a cure? Visit Post
14 Santhera flunks DMD phase 3; Scribe emerges with $20 M; Merck sells off Osteoarthritis drug to Novartis; Research updates on flu vaccine and glioblastoma Visit Post
15 Thumbs down to NKTR-181, Lilly expands its insulin armamentarium Visit Post
16 Emerging drugs bring a positive shift in Global Osteoporosis Market Visit Post
17 World Osteoporosis Day Visit Post
18 FDA approves Bonsity for Osteoporosis treatment Visit Post
19 Juvenescence nets USD 100M; Sarepta DMD drug faces rejection Visit Post
20 Chronic Lower Back Pain Market Analysis Visit Post
21 Chronic Lower Back Pain Therapy Market Visit Post
22 Chronic Lower Back Pain Visit Post
23 Pompe Disease Scenario in Eastern Europe Visit Post
24 Pompe Disease Emerging Markets Visit Post
25 Pompe Disease Treatment Market Visit Post
26 Pompe Disease Market Visit Post
27 Amgen reveals price; Bardy raises $35.5M; Kiadis to Acquire CytoSen; Insitro lands a deal Visit Post
28 New Osteoporosis Drug promises to rebuild Bone Visit Post
29 AbbVie Receives Approval; Kymriah Approved; Shire Gets USFDA Approval; NICE Rejects; Bristol-Myers Squibb’s Opdivo; Eisai and Merck Get USFDA Approval Visit Post
30 Business Cocktail Visit Post
31 Business Cocktail Visit Post
32 Spasticity Visit Post
33 Takeda scores; PhRMA launches; Valeant's Obagi; Ex-Novo executive signs Visit Post
34 Roche, Boehringer tout; Pfizer, Bristol-Myers got sued; FDA commissioner unveils; EpicGenetics expands Visit Post
35 Sarcopenia: “Aging-Associated Strength Loss Condition” Visit Post
36 FDA Approves Sarepta’s Muscular Dystrophy Drug after Months of Debate Visit Post
37 Denali's Impressive Research Portfolio Visit Post
38 Duchenne Muscular Dystrophy Market Visit Post
39 Rheumatoid Arthritis Market, Epidemiology and Market Forecast-2020 Visit Post
40 DelveInsight’s Musculoskeletal disorders based Gene Therapy Reports Visit Post